Treace Medical Concepts Inc TMCI.OQ TMCI.O is expected to show a rise in quarterly revenue when it reports results on November 6 for the period ending September 30 2025
The Ponte Vedra Florida-based company is expected to report a 10.3% increase in revenue to $49.732 million from $45.09 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Treace Medical Concepts Inc is for a loss of 28 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Treace Medical Concepts Inc is $7.00, about 5.9% above its last closing price of $6.59
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -0.29 | -0.29 | -0.28 | Beat | 2.9 |
Mar. 31 2025 | -0.30 | -0.30 | -0.25 | Beat | 17.1 |
Dec. 31 2024 | -0.04 | -0.04 | -0.01 | Beat | 74.1 |
Sep. 30 2024 | -0.27 | -0.27 | -0.25 | Beat | 8 |
Jun. 30 2024 | -0.29 | -0.29 | -0.29 | Met | 0 |
Mar. 31 2024 | -0.30 | -0.30 | -0.30 | Met | 0.9 |
Dec. 31 2023 | -0.09 | -0.09 | -0.10 | Missed | -12.9 |
Sep. 30 2023 | -0.25 | -0.26 | -0.28 | Missed | -7.1 |
This summary was machine generated November 4 at 23:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)